Literature DB >> 28576709

Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.

Imran Jamal1, Vipendra Kumar1, Naman Vatsa1, Shashi Shekhar1, Brijesh Kumar Singh1, Ankit Sharma1, Nihar Ranjan Jana2.   

Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by severe intellectual and developmental disabilities. The disease is caused by the loss of function of maternally inherited UBE3A, a gene that exhibits paternal-specific imprinting in neuronal tissues. Ube3a-maternal deficient mice (AS mice) display many classical features of AS, although, the underlying mechanism of these behavioural deficits is poorly understood. Here we report that the absence of Ube3a in AS mice brain caused aberrant increase in HDAC1/2 along with decreased acetylation of histone H3/H4. Partial knockdown of Ube3a in cultured neuronal cells also lead to significant up-regulation of HDAC1/2 and consequent down-regulation of histones H3/H4 acetylation. Treatment of HDAC inhibitor, sodium valproate, to AS mice showed significant improvement in social, cognitive and motor impairment along with restoration of various proteins linked with synaptic function and plasticity. Interestingly, HDAC inhibitor also significantly increased the expression of Ube3a in cultured neuronal cells and in the brain of wild type mice but not in AS mice. These results indicate that anomalous HDAC1/2 activity might be linked with synaptic dysfunction and behavioural deficits in AS mice and suggests that HDAC inhibitors could be potential therapeutic molecule for the treatment of the disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angelman syndrome; HDAC; Sodium valproate, HDAC inhibitor; Ube3a

Mesh:

Substances:

Year:  2017        PMID: 28576709     DOI: 10.1016/j.nbd.2017.05.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  8 in total

1.  Aberrant aggressive behavior in a mouse model of Angelman syndrome.

Authors:  Lilach Simchi; Hanoch Kaphzan
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

2.  Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.

Authors:  Rebecca Dutta; Jacqueline N Crawley
Journal:  Neuroscience       Date:  2019-11-12       Impact factor: 3.590

Review 3.  Complex neuroprotective and neurotoxic effects of histone deacetylases.

Authors:  Elizabeth A Thomas; Santosh R D'Mello
Journal:  J Neurochem       Date:  2018-04-06       Impact factor: 5.372

4.  Chromatin remodelling complexes in cerebral cortex development and neurodevelopmental disorders.

Authors:  Leora D'Souza; Asha S Channakkar; Bhavana Muralidharan
Journal:  Neurochem Int       Date:  2021-05-06       Impact factor: 3.921

5.  HDAC6-specific inhibitor suppresses Th17 cell function via the HIF-1α pathway in acute lung allograft rejection in mice.

Authors:  Wenyong Zhou; Jun Yang; Gaowa Saren; Heng Zhao; Kejian Cao; Shijie Fu; Xufeng Pan; Huijun Zhang; An Wang; Xiaofeng Chen
Journal:  Theranostics       Date:  2020-05-21       Impact factor: 11.556

6.  Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse.

Authors:  Vipendra Kumar; Tripti Joshi; Naman Vatsa; Brijesh Kumar Singh; Nihar Ranjan Jana
Journal:  Front Mol Neurosci       Date:  2019-11-26       Impact factor: 5.639

7.  Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application.

Authors:  Fan-Cheng Kong; Chun-Lai Ma; Ming-Kang Zhong
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

8.  CIM6P/IGF-2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice.

Authors:  Emmanuel Cruz; Giannina Descalzi; Adam Steinmetz; Helen E Scharfman; Aaron Katzman; Cristina M Alberini
Journal:  Autism Res       Date:  2020-10-27       Impact factor: 5.216

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.